Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Finkel

Showing results (171-180 of 289) with videos related to

Pageof 29
Sort By:
Journal of Clinical Medicine|August 12, 2023
Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor FunctionSally Dunaway Young, Jacqueline Montes, Allan M Glanzman, et al.
Annals of Clinical and Translational Neurology|September 11, 2023
Combination disease-modifying treatment in spinal muscular atrophy: A proposed classificationCrystal M Proud, Eugenio Mercuri, Richard S Finkel, et al.
Journal of Neuromuscular Diseases|July 2, 2023
DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A ResultsRichard S Finkel, John W Day, Samuel Ignacio Pascual Pascual, et al.
Neuromuscular Disorders : NMD|May 31, 2016
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophyCraig M McDonald, Thomas Meier, Thomas Voit, et al.
Plos One|May 5, 2012
Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical studyRichard S Finkel, Thomas O Crawford, Kathryn J Swoboda, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World DataCostanza Cutrona, Roberto de Sanctis, Giorgia Coratti, et al.
Human Molecular Genetics|November 1, 1996
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophyE M McNally, D Duggan, J R Gorospe, et al.
Lancet (London, England)|December 13, 2016
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Circulation|August 13, 2003
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet SubstudyVictor L Serebruany, Alexander H Glassman, Alex I Malinin, et al.
The Lancet. Child & Adolescent Health|June 5, 2021
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Pageof 29

Showing results (171-180 of 289) with videos related to

Sort By:
Pageof 29
Journal of Clinical Medicine|August 12, 2023
Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor FunctionSally Dunaway Young, Jacqueline Montes, Allan M Glanzman, et al.
Annals of Clinical and Translational Neurology|September 11, 2023
Combination disease-modifying treatment in spinal muscular atrophy: A proposed classificationCrystal M Proud, Eugenio Mercuri, Richard S Finkel, et al.
Journal of Neuromuscular Diseases|July 2, 2023
DEVOTE Study Exploring Higher Dose of Nusinersen in Spinal Muscular Atrophy: Study Design and Part A ResultsRichard S Finkel, John W Day, Samuel Ignacio Pascual Pascual, et al.
Neuromuscular Disorders : NMD|May 31, 2016
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophyCraig M McDonald, Thomas Meier, Thomas Voit, et al.
Plos One|May 5, 2012
Candidate proteins, metabolites and transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) clinical studyRichard S Finkel, Thomas O Crawford, Kathryn J Swoboda, et al.
Journal of Neuromuscular Diseases|November 19, 2023
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World DataCostanza Cutrona, Roberto de Sanctis, Giorgia Coratti, et al.
Human Molecular Genetics|November 1, 1996
Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophyE M McNally, D Duggan, J R Gorospe, et al.
Lancet (London, England)|December 13, 2016
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Circulation|August 13, 2003
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet SubstudyVictor L Serebruany, Alexander H Glassman, Alex I Malinin, et al.
The Lancet. Child & Adolescent Health|June 5, 2021
Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation studyRichard S Finkel, Claudia A Chiriboga, Jiri Vajsar, et al.
Pageof 29